MedTrace Logo

Propionic Acid for Multiple Sclerosis: Safety and Benefits

NCT07595081 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).

Conditions

Interventions

DIETARY_SUPPLEMENT

Propionic acid 1000 mg capsule

Patients will receive propionic acid as add on MS treatment.

Sponsors & Collaborators

  • Salzburger Landeskliniken

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-05-01
Completion
2025-12-12

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07595081 on ClinicalTrials.gov